Lunacalcipol

Drug Profile

Lunacalcipol

Alternative Names: CTA-018; CTA018 Capsule; CTA018 Cream; CTA018 Injection; MT-2832

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Johns Hopkins University
  • Developer Cytochroma; OPKO Health
  • Class Antipsoriatics; Vitamin D analogues
  • Mechanism of Action Calcitriol stimulants; CYP24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Secondary hyperparathyroidism
  • Discontinued Psoriasis

Most Recent Events

  • 23 May 2016 OPKO Health plans a phase IIb trial for Secondary hyperparathyroidism in USA (IV) (OPKO Health website, May 2016)
  • 24 Apr 2014 Phase-II clinical trials in Secondary hyperparathyroidism in USA (IV)
  • 04 Mar 2013 Cytochroma has been acquired by OPKO Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top